119 related articles for article (PubMed ID: 38862137)
1. Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice.
Chen G; Yu Y; Zhu Y; Nagashimada M; Wang Y; Nagata N; Xu L
Endocrinology; 2024 May; 165(7):. PubMed ID: 38862137
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
3. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
[TBL] [Abstract][Full Text] [Related]
4. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.
Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T
Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616
[TBL] [Abstract][Full Text] [Related]
5. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
[TBL] [Abstract][Full Text] [Related]
6. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
Tacke F
Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
[TBL] [Abstract][Full Text] [Related]
7. Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor γ.
Zhong X; Liu H
J Gastroenterol Hepatol; 2018 Feb; 33(2):524-532. PubMed ID: 28670854
[TBL] [Abstract][Full Text] [Related]
8. DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice.
Sakai Y; Chen G; Ni Y; Zhuge F; Xu L; Nagata N; Kaneko S; Ota T; Nagashimada M
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32790863
[TBL] [Abstract][Full Text] [Related]
9. Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E.
Ni Y; Nagashimada M; Zhuge F; Zhan L; Nagata N; Tsutsui A; Nakanuma Y; Kaneko S; Ota T
Sci Rep; 2015 Nov; 5():17192. PubMed ID: 26603489
[TBL] [Abstract][Full Text] [Related]
10. Chronic alcohol-induced neuroinflammation involves CCR2/5-dependent peripheral macrophage infiltration and microglia alterations.
Lowe PP; Morel C; Ambade A; Iracheta-Vellve A; Kwiatkowski E; Satishchandran A; Furi I; Cho Y; Gyongyosi B; Catalano D; Lefebvre E; Fischer L; Seyedkazemi S; Schafer DP; Szabo G
J Neuroinflammation; 2020 Oct; 17(1):296. PubMed ID: 33036616
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice.
Ambade A; Lowe P; Kodys K; Catalano D; Gyongyosi B; Cho Y; Iracheta-Vellve A; Adejumo A; Saha B; Calenda C; Mehta J; Lefebvre E; Vig P; Szabo G
Hepatology; 2019 Mar; 69(3):1105-1121. PubMed ID: 30179264
[TBL] [Abstract][Full Text] [Related]
12. Lycopene Alleviates Obesity-Induced Inflammation and Insulin Resistance by Regulating M1/M2 Status of Macrophages.
Chen G; Ni Y; Nagata N; Zhuge F; Xu L; Nagashimada M; Yamamoto S; Ushida Y; Fuke N; Suganuma H; Kaneko S; Ota T
Mol Nutr Food Res; 2019 Nov; 63(21):e1900602. PubMed ID: 31408586
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
[TBL] [Abstract][Full Text] [Related]
14. CC chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice.
Xu L; Chen Y; Nagashimada M; Ni Y; Zhuge F; Chen G; Li H; Pan T; Yamashita T; Mukaida N; Kaneko S; Ota T; Nagata N
Metabolism; 2021 Dec; 125():154914. PubMed ID: 34656648
[TBL] [Abstract][Full Text] [Related]
15. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
Ratziu V; Sanyal A; Harrison SA; Wong VW; Francque S; Goodman Z; Aithal GP; Kowdley KV; Seyedkazemi S; Fischer L; Loomba R; Abdelmalek MF; Tacke F
Hepatology; 2020 Sep; 72(3):892-905. PubMed ID: 31943293
[TBL] [Abstract][Full Text] [Related]
16. Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages.
Chen G; Ni Y; Nagata N; Xu L; Zhuge F; Nagashimada M; Kaneko S; Ota T
Lab Invest; 2019 Sep; 99(9):1335-1348. PubMed ID: 31019294
[TBL] [Abstract][Full Text] [Related]
17. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
18. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
[TBL] [Abstract][Full Text] [Related]
19. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
20. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
